0.06
+0.0005(+0.83%)
Currency In USD
Address
285 East Grand Avenue
South San Francisco, CA 94080
United States of America
Phone
650 416 1192
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Employees
16
First IPO Date
October 04, 2018
| Name | Title | Pay | Year Born |
| Dr. Anirvan Ghosh Ph.D. | Chief Executive Officer & Director | 953,706 | 1965 |
| Dr. Nathaniel E. David A.B., Ph.D. | Co-Founder & Independent Director | 49,500 | 1968 |
| Mr. Alexander Hieu Nguyen J.D. | Chief Legal Officer & Head of Operations | 622,968 | 1978 |
| Ms. Alicia Tozier M.B.A. | Chief Strategy Officer | 0 | N/A |
| Dr. Przemyslaw Sapieha Ph.D. | Chief Scientist | 0 | N/A |
| Dr. Jan M. van Deursen Ph.D. | Founder | 0 | N/A |
| Dr. Federico Grossi M.D., Ph.D. | Chief Medical Officer | 0 | 1974 |
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.